SHH:600993
Mayinglong Pharmaceutical Group Co., Ltd. · SHH · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 13:08 UTC
Last close
n/aCNY
Market data
18.6xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
- Computed from the filing for 2025
25.9%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
15.0%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
12.4%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.02Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- CNY
- computed
What it pays out is the furthest below its sector's middle: 0.37 against 0.54 on the market's range.
All from 100
lens 2 of 9Sales
184Profit
232Shares in issue
99.8Sales is at 184, Profit is at 232, Shares in issue is at 100, against 100 in 2016.
Sales is at 184, Profit is at 232, Shares in issue is at 100, against 100 in 2016.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales, where the first year is 100184
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Profit, where the first year is 100232
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Shares in issue, where the first year is 100100
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY